The diagnostic methods and treatment modalities of soft tissue sarcomas have evolved with the multidisciplinary approach. The soft tissue sarcoma team must have specialists capable of using and combining modern methods of radiology and pathology, cytogenetics, tumour surgery, tissue transfer techniques, radiotherapy and chemotherapy for optimal local and systemic treatment. Limb sparing surgery combined with radiotherapy has lowered the amputation rate and maintained low rates of local recurrence. Reconstructive surgery facilitates treatment of patients with soft tissue sarcoma by permitting tumour resection with adequate margins, protects vital structures, enables early postoperative radiation therapy, maintains extremity length, and if necessary assists in palliative procedures. The ability to maintain function and aesthetics after tumour resection, and effective palliation improves the quality of life for these patients. Early recognition and appropriate referral to a tumour centre improve the outcome.
DEFINITION AND EPIDEMIOLOGY
Soft tissue sarcomas (STS) are group of malignant tumours originating from extra-skeletal mesenchymal tissue and neuro-ectodermal tissues. They include the tumours of connective tissues, such as muscle, fat, synovia and fibrous tissue, and also those of the Schwann cells (1). STS account 6.5 % of childhood malignancies. In adults they constitute about 1%of all the malignancies, but may account for 2 % of cancer deaths. STS have steadily increasing incidence with age, and the median age at diagnosis is about 60 years. There is slight male predominance. The annual incidence is about 2-4 cases per 100,000.
Because STS occurs in multiple forms, it is probable that many causes are involved. Usually in indi-lump, which has been increasing in size over a period of months. A painful mass suggests compression or involvement of neurovascular structures or an inflammatory process. About 1/3 of the tumours are superficial, most of them are located subcutaneously, presenting with firm, growing lump, fixed to the underlying structures.
The deep tumours can reach large dimensions especially in limb girdles without causing any symptoms. They can be noticed for the first time by the patient in connection with a trauma. The area is examined by the patient, or there is a sudden bleeding in the tumour calling attention. Real or postulated trauma may cause confusion and the symptoms are easily related to the injury. Diagnosis is often delayed due to lack of any symptoms in centrally located, deep sarcomas, or misinterpretation of a peripherally located mass. Better patient and doctor education is required (6).
DIAGNOSIS
Clinical examination, a plain radiograph and ultrasonogram confirm the presence of a soft tissue tumour. Usually ultrasonography does not suffice as the only radiological investigation. Therefore MRI examination, or if it is contraindicated, a CT examination should be performed.
A histopathological diagnosis is recommended for all soft tissue masses. The fine needle and/or core biopsies are usually guided with ultrasonography and they are taken after imaging procedures, because biopsies will cause disturbance in MRI and CT images, which give important information for optimal guidance of the needle samples (the exact anatomy and specific areas of the tumour). If indicated, biopsies can be guided also with CT or MRI. Open biopsies are only exceptionally performed. Chest X-ray should be routinely taken and chest CT is indicated in all patients with high grade sarcomas (7, 8), because approximately 15 % of all adult sarcomas present with metastatic disease, usually as multiple lung nodules (9).
HISTOPATHOLOGY AND THE ROLE OF THE PATHOLOGIST
At present more than 100 different histological entities of soft tissue tumours have been described, some of which are extremely rare (10) . Many benign and malignant tumours have to taken into count in the differential diagnosis of STS (Table 1) . Benign tumours greatly outnumber the malignant ones. The most common soft tissue sarcomas in adults are malignant fibrous histiocytoma (MFH), liposarcoma, fibrosarcoma, leiomyosarcoma and synovial sarcoma.
A histopatological diagnosis is usually obtained with fine needle and/or core-biopsy. The adequate classification demands an experienced pathologist and use of immunohistochemistry and often also other techniques such as cytogenetics. Most malignant STS contain chromosome aberrations, some of which are diagnostic for particular tumour types. Upon reclassification in sarcoma centers, more than 1/3 diagnoses had to be changed from the original diagnosis given in the hospitals from which patient were referred.
In addition to the histogenetic classification, also the grade of malignancy has to be evaluated. The grading is based on assessment of mitoses, necrosis and degree of differentiation (11) . In Scandinavia four grades are used; low malignancy (grades I and II) and high malignancy (grades III and IV). Also division into three grades (I low, II intermediate, and III high), is widely used. In both classifications, highgrade tumours are more common than low-grade tumours, and it is uncommon to have a deep low grade tumour (12) .
Some types of STS strongly correlate to the grade. Thus dermatofibrosarcoma protuberans is a low grade tumour, while primitive neuroectodermal tumour (PNET), and extra-skeletal Ewing tumour, or angiosarcomas are high grade tumours by definition. On the other hand, leiomyosarcoma, MFH and liposarcoma can present in any grades.
The contribution of the pathologist is important. Correct pathological diagnosis should include the histologic type, subtype and grade of the tumour. This information will be correlated with size, site, clinical and radiological presentation, and will determine the biology and the treatment of the tumour.
After surgery the tumour specimen is sent to the pathologist for fresh examination (photography, weighing, measurement of dimensions, samples for histology and cell biology) and the resection margins are determined in consultation with the surgeon. The sensitivity of the tumour to previous radiation or chemotherapy, if they have been given, is also determined (13) .
The growth behaviour of STS can be variable. The tumour can be microscopically infiltrative despite it looks macroscopically encapsulated, there may be skip metastasis away from the main tumour, or there may be multifocal growth of the primary or recurrent tumour. Therefore, the estimation of margins can be difficult.
Regional lymph node metastasis occurs only in 3.9-5.5 % cases in large series of STS. The incidence (14) .
TREATMENT Surgical excision has been the mainstay of the therapy for STS. In the past, a soft-tissue sarcoma in the extremities was treated with local resection that often resulted in local recurrence and amputation. At present, treatment of these tumours consists of wide or marginal excision, and if indicated adequate primary reconstruction of the tissue defect, and radiotherapy. As sarcomas respect fascial tissues for a long time, they are commonly resected in their anatomical unit with the surrounding fascial layer. The resection margin in muscle, fat and skin should be 2-3cm. The variety of localizations in all regions of the body require individual planning. Several things must be taken into account (Table 2 ). The main factors determining whether tumour can be resected, are tissue invasion, size and anatomical location
The amputation rate for extremity STS can be reduced by the use of reconstructive procedures, particularly myocutaneous pedicled flaps to the proxi-mal limbs and limb girdles, and free vascularized flaps to more distal sites of the extremities (15, 16, 17) . If wide surgical margins are not obtained without seriously compromising limb function, marginal excision is performed and postoperative radiotherapy is applied. Radiotherapy should be given to lowgrade tumours with same principles as for highgrade tumours. In most cases limb salvage is possible and the amputation rate in most recent publications has been 5-15 %. Primary major amputation can only be justified in cases, where the tumour infiltrates major neurovascular structures and other option have been consider (down staging with oncological therapy, marginal excision and the use of major reconstructive surgery) (18) .
In our material (tertiary referral centre) the amputation rate of upper extremity sarcomas was 15 % compared to 8 % in lower extremity. This reflects the fact that adequate operative margins are more diffi- Fig. 1A , B, C. A 62-year-old man with a recurrent high grade sarcoma in the anterior chest wall. The planned resection and donor area of microvascular musculocutaneous tensor fascia latae (TFL) flap are indicated (A). Full-thickness chest wall resection has been performed, and chest wall stability is attained with free rib grafts (B) and a polypropylene mesh. The defect is covered with the free TFL flap (C). Preoperative planning of STS excision.
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1. Size and location of the tumour 2. Dissemination of the tumour 3. Histopathology and grade (I-IV) of the tumour 4.
Preceding procedures (open biopsy, attempted excision, radiation therapy) 5. Indications and options for reconstruction with local, pedicled or microvascular flaps 6. General health and age of the patient cult to achieve in upper extremity, because of scantiness of the soft tissue. Moreover, epithelioid sarcoma (typically an upper extremity tumour) demands an extensive resection or a major amputation. In cutaneous, subcutaneous or intramuscular tumours the local recurrence-free survival rate at 5 years was 100 % in upper extremity. Extracompartmental location significantly impaired local recurrence-free, metastases-free, disease-free and disease-specific overall survival (15, 16) .
Local control is best achieved by treating tumours early and adequately in the first operation (16) . Poorly planned resections or radiotherapy often leave inadequate margins or residual tumour, and demand an extensive or mutilating re-excision (19) .
All patients do not require reconstructive surgery after the tumour resection. However, there are many cases where reconstructive surgery is vital for the re-covery or limb salvage, or substantially facilitates the further treatment (4). If vital organs remain exposed (abdominal, chest cavity, or dura/brain), they must be covered immediately with well vascularized tissue (Table 3) . Also major nerves, blood vessels, prosthetic joints and bone allografts must be covered with healthy tissue. Reconstruction is performed with local, pedicular or microvascular flaps, using skin, fasciocutaneus or muscle flaps as indicated.
The transfer of healthy, well-vascularized tissue to a previously irradiated wound will facilitate the wound healing. Primary wound closure after resection of a large or recurrent sarcoma easily leads to skin necrosis and wound dehiscence (20) . Excessive undermining of the skin, tension along the suture line and "dead space" after resection, especially after preoperative radiotherapy, are the most common factors associated with wound healing problems (21) .
Assistance with palliative procedures is another way reconstructive surgery contributes to treatment of STS. Severe distressing symptoms, such as pain, bleeding and discharging wounds, may require excision and reconstruction with musculocutaneous flap. A paretic, aching, infected oedematous, useless limb should be amputated (18) . This may demand a flap reconstruction (22) .
Radiotherapy combined with the primary operation improves the local control, but it has no effect on disease-free survival or overall survival (23, 24) . In certain cases (extensive tumours) preoperative radiotherapy may be considered. Patients with locally advanced STS, which are considered primarily unresectable   TABLE 3 Indications for immediate soft tissue reconstruction after STS excision.
1. Vital cavity/organ remains exposed (thorax, abdomen, dura, brain) 2. Exposed major nerves, tendons, vessels, bones, joints or replacement prostheses 3. Large tissue defect, wound cavity or tension at suture line 4. Planned postoperative radiotherapy or chemotherapy demanding rapid and uneventful wound healing in a high risk wound Fig. 2A , B, C. 40-year-old man with a high grade sarcoma in the lower arm (A). Wide excision including skin, subcutaneous fat, fascia and muscle is performed (B). The resected specimen is marked and sent fresh to the pathologist. The reconstruction is performed with microvascular anterolateral thigh flap (C).
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C might be downstaged with individually tailored oncological treatment (preoperative radiotherapy and/ or chemotherapy). This may allow subsequent limb salvage surgery (18) . This approach is valuable also in cases, where the tumours is already disseminated, and mutilating amputation does not seem justified. However, preoperative radiotherapy is associated with greater risk of wound complications than postoperative radiotherapy (26, 27) , and reconstructive procedures should be liberally utilized. Certain histological types of STS also in the adolescence (rhabdomyosarcoma, extrasceletal Ewing's sarcoma, PNET) are treated with specific treatment protocols including chemotherapy, radiotherapy and operation (28) . The oncological treatment of STS patients with inoperable disseminated disease is palliative. Tumour regression can be achieved in 10-30 % of cases with chemotherapy. Radiotherapy can alleviate symptoms caused by solitary metastasis. Surgical excision of lung metastases from STS is well accepted and should be considered if preoperative evaluation indicates that complete clearance of the metastases is possible (29) .
PROGNOSTIC FACTORS
Five-year survival rate for high-grade sarcomas is about 50 % and for low-grade sarcomas 90 %. The prognosis of STS depends on tumour grade, tumour size, histological diagnosis, depth of the tumour and adequacy of the initial treatment. These prognostic factors seem to have slightly different importance in different studies and in aspects of STS prognosis (local recurrence rate, distant metastasis and tumour related death). In most studies adverse prognostic factors for local recurrence were microscopically positive margins, tumour size and, in some studies, patient age over 50 years. Tumour size and grade are the major determinants of death from tumour (30, 31) . Primarily superficial tumours of the extremities have better prognosis than deep or extracompartmental tumours (16, 30) .
Adequacy of local treatment, both surgical margin and radiotherapy, affects the risk of local recurrence (30) . The first operation should be properly planned and performed, because unplanned, intralesional excision of a soft tissue mass, which seems clinically benign but later proves to be malignant, can have potentially devastating consequences (19) . Inadequate primary surgery makes curative excision more difficult and extensive or it may lead to amputation. However, even after inadequate primary resection, a second operation, when indicated and possible, should be liberally applied, because re-excision affects the final outcome (32) .
As diagnostic methods and treatment strategies for STS continue to be refined, it is important for the outcome of the patients, that the treatment is takes place in hospitals with expertise in soft tissue sarcomas. Close collaboration with many specialities (radiology, pathology, cytogenetics, oncology and different subspecialities of surgery) is important. These tumours should be treated in a university multidisciplinary sarcoma team (7, 33).
